Tracking a drug Combo's Real-Life fight against melanoma return
NCT ID NCT04961619
Summary
This study observed 39 patients in Turkey with high-risk melanoma who had surgery to remove their cancer. Doctors then gave them a two-drug combination (dabrafenib and trametinib) to try to prevent the cancer from coming back. The main goal was to see how long patients stayed cancer-free and to track the side effects and practical use of these medications in everyday hospital settings.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Antalya, Konyaalti, 07070, Turkey (Türkiye)
-
Novartis Investigative Site
Edirne, Merkez, 22030, Turkey (Türkiye)
-
Novartis Investigative Site
Bursa, Nilufer, 16059, Turkey (Türkiye)
-
Novartis Investigative Site
Diyarbakır, Sur, 21280, Turkey (Türkiye)
-
Novartis Investigative Site
Istanbul, Uskudar, 34668, Turkey (Türkiye)
-
Novartis Investigative Site
Adana, Yuregir, 1230, Turkey (Türkiye)
-
Novartis Investigative Site
Ankara, 06520, Turkey (Türkiye)
-
Novartis Investigative Site
Izmir, 35100, Turkey (Türkiye)
-
Novartis Investigative Site
Kecioren Ankara, 06010, Turkey (Türkiye)
Conditions
Explore the condition pages connected to this study.